CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.

Under these conditions, PD-0332991 had a highly significant effect on the proliferation of the tumor cells as determined by Ki67 staining (Figure 2D ).

also in 132,142 other papers